ResMed Operating Cycle from 2010 to 2026
| RMD Stock | USD 263.54 12.42 4.50% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 267 | Current Value 244.38 | Quarterly Volatility 29.01969521 |
Check ResMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ResMed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 284.7 M, Interest Expense of 11.9 M or Total Revenue of 6.2 B, as well as many indicators such as Price To Sales Ratio of 4.31, Dividend Yield of 0.0134 or PTB Ratio of 4.78. ResMed financial statements analysis is a perfect complement when working with ResMed Valuation or Volatility modules.
ResMed | Operating Cycle | Build AI portfolio with ResMed Stock |
Analyzing ResMed's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing ResMed's current valuation and future prospects.
Latest ResMed's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of ResMed Inc over the last few years. It is ResMed's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ResMed's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
ResMed Operating Cycle Regression Statistics
| Arithmetic Mean | 207.66 | |
| Geometric Mean | 205.85 | |
| Coefficient Of Variation | 13.97 | |
| Mean Deviation | 24.27 | |
| Median | 193.28 | |
| Standard Deviation | 29.02 | |
| Sample Variance | 842.14 | |
| Range | 95.3524 | |
| R-Value | 0.73 | |
| Mean Square Error | 423.80 | |
| R-Squared | 0.53 | |
| Significance | 0.001 | |
| Slope | 4.18 | |
| Total Sum of Squares | 13,474 |
ResMed Operating Cycle History
About ResMed Financial Statements
ResMed stakeholders use historical fundamental indicators, such as ResMed's Operating Cycle, to determine how well the company is positioned to perform in the future. Although ResMed investors may analyze each financial statement separately, they are all interrelated. For example, changes in ResMed's assets and liabilities are reflected in the revenues and expenses on ResMed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ResMed Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 267.00 | 244.38 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out the analysis of ResMed Correlation against competitors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Health Care Equipment & Supplies sector continue expanding? Could ResMed diversify its offerings? Factors like these will boost the valuation of ResMed. Anticipated expansion of ResMed directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ResMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.145 | Dividend Share 2.26 | Earnings Share 10.1 | Revenue Per Share | Quarterly Revenue Growth 0.11 |
ResMed Inc's market price often diverges from its book value, the accounting figure shown on ResMed's balance sheet. Smart investors calculate ResMed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ResMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ResMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ResMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.